Navigation Links
Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit

CHICAGO, Sept. 10 /PRNewswire/ -- Celsis In Vitro, Inc. (Celsis IVT) announced today that the United States District Court for the Northern District of Illinois in Chicago has entered a preliminary injunction against CellzDirect Inc., Invitrogen Corporation, and Life Technologies (the Defendants) due to their infringement of U.S. Patent No. 7,604,929 (the Liverpool™ patent).  Life Technologies of Carlsbad, California (Nasdaq: LIFE) is the parent of Invitrogen and CellzDirect.  The Liverpool patent relates to methods for producing multi-cryopreserved hepatocytes and methods for using multi-cryopreserved hepatocytes to investigate in vitro drug metabolism.

According to the terms of the injunction, the Defendants and those acting in collaboration with them are enjoined from using the claimed methods of the Liverpool patent that relate to producing multi-cryopreserved hepatocytes and the use of multi-cryopreserved hepatocytes to investigate in vitro drug metabolism.  The Defendants are further barred from selling or offering to sell multi-cryopreserved hepatocytes including restrictions on products presently held in inventory.

In addition, the Defendants and those acting in collaboration with them are enjoined from inducing, aiding and abetting, or encouraging others to practice the claimed methods related to the use of multi-cryopreserved hepatocytes to investigate in vitro drug metabolism; for example by encouraging or supporting their customers who are in possession of Defendant-branded multi-cryopreserved products in their continued use to investigate in vitro drug metabolism.

Celsis IVT has alleged that certain processes and methods performed by CellzDirect and Invitrogen associated with their in vitro drug testing services and their pooled cryopreserved hepatocyte products willfully infringe one or more claims of Liverpool patent.  Celsis IVT has also alleged that the Defendants are selling products from infringing methods, providing infringing services, and inducing infringement of the LiverPool patent.  In addition to the preliminary injunctive relief ordered, Celsis IVT is seeking monetary damages and a permanent injunction.  Adam G. Kelly, Jordan A. Sigale, and Julie L. Langdon of Loeb & Loeb LLP represent Celsis IVT.

"We are encouraged by the Court's decision to award Celsis IVT injunctive relief in this case.  Patented innovations must be protected from infringement if research and development is to continue in the life sciences industry," said Jay LeCoque, CEO of Celsis.  "Companies that produce infringing products, piggy-backing on years of research and development by other scientists, have no costs to recoup. It's all too easy for them to offer products for sale at significant discounts compared to patented products that must recoup major R&D investments.  This type of predatory pricing employed by Invitrogen and CellzDirect has done much to undermine in the minds of our customers the perceived value of new product innovations in the ADME-Tox industry.  We remain hopeful that the defendants will realize the serious impact of such a precedent on the entire life sciences industry, and that they will work with us to properly resolve this issue."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis Holdings, Inc., itself a subsidiary of Celsis International Ltd, is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development.  Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization.  Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research.  Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Learn more at

About Celsis International Ltd

Chicago-based Celsis International Ltd is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries.  Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers.  Celsis' extensive client base includes all 25 of the top 25 pharmaceutical companies worldwide.

SOURCE Celsis In Vitro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
9. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):